Literature DB >> 12743807

Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis.

Andrew Jonathan Nok1.   

Abstract

Human African trypanosomiasis (HAT), otherwise known as sleeping sickness, has remained a disease with no effective treatment. Recent progress in HAT research suggests that a vaccine against the disease is far from being successful. Also the emergence of drug-resistant trypanosomes makes further work in this area imperative. So far the treatment for the early stage of HAT involves the drugs pentamidine and suramin which have been very successful. In the second stage of the disease, during which the trypanosomes reside in the cerebrospinal fluid (CSF), treatment is dependent exclusively on the arsenical compound melarsoprol. This is largely due to the inability to find compounds that can cross the blood brain barrier and kill the CSF-residing trypanosomes. This review summarises our current understanding on the treatment of HAT.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12743807     DOI: 10.1007/s00436-002-0799-9

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  54 in total

Review 1.  Chemotherapeutic approaches to protozoa: kinetoplastida--current level of knowledge and outlook.

Authors:  A Harder; G Greif; A Haberkorn
Journal:  Parasitol Res       Date:  2001-09       Impact factor: 2.289

2.  Problems for the chemotherapy of human African trypanosomiasis.

Authors:  Michael P. Barrett
Journal:  Curr Opin Infect Dis       Date:  2000-12       Impact factor: 4.915

3.  Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia.

Authors:  S L Soignet; W P Tong; S Hirschfeld; R P Warrell
Journal:  Cancer Chemother Pharmacol       Date:  1999       Impact factor: 3.333

Review 4.  Recent research on the biological activity of suramin.

Authors:  T E Voogd; E L Vansterkenburg; J Wilting; L H Janssen
Journal:  Pharmacol Rev       Date:  1993-06       Impact factor: 25.468

5.  Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor viruses.

Authors:  E De Clercq
Journal:  Cancer Lett       Date:  1979-11       Impact factor: 8.679

Review 6.  The biochemical basis of arsenical-diamidine crossresistance in African trypanosomes.

Authors:  M P Barrett; A H Fairlamb
Journal:  Parasitol Today       Date:  1999-04

7.  The efficacy of pentamidine in the treatment of early-late stage Trypanosoma brucei gambiense trypanosomiasis.

Authors:  F Doua; T W Miezan; J R Sanon Singaro; F Boa Yapo; T Baltz
Journal:  Am J Trop Med Hyg       Date:  1996-12       Impact factor: 2.345

8.  Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment.

Authors:  C Burri; J Keiser
Journal:  Trop Med Int Health       Date:  2001-05       Impact factor: 2.622

9.  The phosphoglycerate kinases from Trypanosoma brucei. A comparison of the glycosomal and the cytosolic isoenzymes and their sensitivity towards suramin.

Authors:  O Misset; F R Opperdoes
Journal:  Eur J Biochem       Date:  1987-02-02

10.  Purification of the low density lipoprotein receptor, an acidic glycoprotein of 164,000 molecular weight.

Authors:  W J Schneider; U Beisiegel; J L Goldstein; M S Brown
Journal:  J Biol Chem       Date:  1982-03-10       Impact factor: 5.157

View more
  22 in total

Review 1.  Parasitic central nervous system infections in immunocompromised hosts: malaria, microsporidiosis, leishmaniasis, and African trypanosomiasis.

Authors:  Melanie Walker; James G Kublin; Joseph R Zunt
Journal:  Clin Infect Dis       Date:  2005-11-23       Impact factor: 9.079

Review 2.  Chemotherapy for second-stage human African trypanosomiasis.

Authors:  Vittoria Lutje; Jorge Seixas; Adrian Kennedy
Journal:  Cochrane Database Syst Rev       Date:  2013-06-28

3.  Trypanosome Transmission Dynamics in Tsetse.

Authors:  Serap Aksoy; Brian L Weiss; Geoff M Attardo
Journal:  Curr Opin Insect Sci       Date:  2014-09       Impact factor: 5.186

4.  Inhibitors of LexA Autoproteolysis and the Bacterial SOS Response Discovered by an Academic-Industry Partnership.

Authors:  Charlie Y Mo; Matthew J Culyba; Trevor Selwood; Jeffrey M Kubiak; Zachary M Hostetler; Anthony J Jurewicz; Paul M Keller; Andrew J Pope; Amy Quinn; Jessica Schneck; Katherine L Widdowson; Rahul M Kohli
Journal:  ACS Infect Dis       Date:  2018-01-08       Impact factor: 5.084

Review 5.  Adenotrophic viviparity in tsetse flies: potential for population control and as an insect model for lactation.

Authors:  Joshua B Benoit; Geoffrey M Attardo; Aaron A Baumann; Veronika Michalkova; Serap Aksoy
Journal:  Annu Rev Entomol       Date:  2014-10-17       Impact factor: 19.686

Review 6.  Neuroparasitic infections: cestodes, trematodes, and protozoans.

Authors:  M D Walker; J R Zunt
Journal:  Semin Neurol       Date:  2005-09       Impact factor: 3.420

7.  High-throughput analysis of an RNAi library identifies novel kinase targets in Trypanosoma brucei.

Authors:  Zachary B Mackey; Kyriacos Koupparis; Mari Nishino; James H McKerrow
Journal:  Chem Biol Drug Des       Date:  2011-07-14       Impact factor: 2.817

8.  Computer-aided discovery of Trypanosoma brucei RNA-editing terminal uridylyl transferase 2 inhibitors.

Authors:  Ozlem Demir; Mehdi Labaied; Chris Merritt; Ken Stuart; Rommie E Amaro
Journal:  Chem Biol Drug Des       Date:  2014-06-05       Impact factor: 2.817

9.  Antiprotozoal activity of ferroquine.

Authors:  S Pomel; C Biot; C Bories; P M Loiseau
Journal:  Parasitol Res       Date:  2012-11-15       Impact factor: 2.289

10.  Repurposing human PDE4 inhibitors for neglected tropical diseases. Evaluation of analogs of the human PDE4 inhibitor GSK-256066 as inhibitors of PDEB1 of Trypanosoma brucei.

Authors:  Stefan O Ochiana; Nicholas D Bland; Luca Settimo; Robert K Campbell; Michael P Pollastri
Journal:  Chem Biol Drug Des       Date:  2014-11-18       Impact factor: 2.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.